CA2708822A1 - Kinesin inhibitors as cancer therapeutics - Google Patents

Kinesin inhibitors as cancer therapeutics Download PDF

Info

Publication number
CA2708822A1
CA2708822A1 CA2708822A CA2708822A CA2708822A1 CA 2708822 A1 CA2708822 A1 CA 2708822A1 CA 2708822 A CA2708822 A CA 2708822A CA 2708822 A CA2708822 A CA 2708822A CA 2708822 A1 CA2708822 A1 CA 2708822A1
Authority
CA
Canada
Prior art keywords
substituted
carcinoma
compound
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2708822A
Other languages
English (en)
French (fr)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A. Renhowe
Annette Olga Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2708822(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2708822A1 publication Critical patent/CA2708822A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2708822A 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics Abandoned CA2708822A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14
US61/013,966 2007-12-14
PCT/EP2008/067412 WO2009077448A1 (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Publications (1)

Publication Number Publication Date
CA2708822A1 true CA2708822A1 (en) 2009-06-25

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708822A Abandoned CA2708822A1 (en) 2007-12-14 2008-12-12 Kinesin inhibitors as cancer therapeutics

Country Status (30)

Country Link
US (2) US8252832B2 (enExample)
EP (1) EP2229170B1 (enExample)
JP (1) JP5501976B2 (enExample)
KR (1) KR20100098394A (enExample)
CN (1) CN101939005B (enExample)
AR (1) AR069676A1 (enExample)
AU (1) AU2008337570B2 (enExample)
BR (1) BRPI0821248A2 (enExample)
CA (1) CA2708822A1 (enExample)
CL (1) CL2008003707A1 (enExample)
CO (1) CO6290651A2 (enExample)
CR (1) CR11412A (enExample)
DO (1) DOP2010000175A (enExample)
EA (1) EA018014B1 (enExample)
EC (1) ECSP10010248A (enExample)
ES (1) ES2459442T3 (enExample)
GE (1) GEP20125647B (enExample)
GT (1) GT201000172A (enExample)
IL (1) IL205831A0 (enExample)
MA (1) MA31872B1 (enExample)
MY (1) MY150214A (enExample)
NI (1) NI201000091A (enExample)
NZ (1) NZ585142A (enExample)
PA (1) PA8807801A1 (enExample)
PE (1) PE20091451A1 (enExample)
SM (1) SMP201000095B (enExample)
TN (1) TN2010000204A1 (enExample)
TW (1) TW200930704A (enExample)
UY (1) UY31532A1 (enExample)
WO (1) WO2009077448A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8748626B2 (en) 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552510A (en) * 2004-06-18 2010-12-24 Novartis Vaccines & Diagnostic N-(1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2,2-dimethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
MX2009007260A (es) 2007-01-05 2009-07-10 Novartis Ag Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).

Also Published As

Publication number Publication date
US8252832B2 (en) 2012-08-28
EA201000900A1 (ru) 2011-02-28
TW200930704A (en) 2009-07-16
EP2229170B1 (en) 2014-01-22
CL2008003707A1 (es) 2009-06-05
UY31532A1 (es) 2009-08-03
BRPI0821248A2 (pt) 2015-06-16
KR20100098394A (ko) 2010-09-06
PE20091451A1 (es) 2009-10-19
PA8807801A1 (es) 2009-07-23
WO2009077448A1 (en) 2009-06-25
CR11412A (es) 2010-06-30
EP2229170A1 (en) 2010-09-22
JP5501976B2 (ja) 2014-05-28
NI201000091A (es) 2011-03-15
GT201000172A (es) 2012-04-30
SMAP201000095A (it) 2010-09-10
CN101939005A (zh) 2011-01-05
US20090239922A1 (en) 2009-09-24
ECSP10010248A (es) 2010-07-30
CN101939005B (zh) 2015-12-16
US20130012560A1 (en) 2013-01-10
JP2011506402A (ja) 2011-03-03
ES2459442T3 (es) 2014-05-09
TN2010000204A1 (en) 2011-11-11
MA31872B1 (fr) 2010-11-01
DOP2010000175A (es) 2010-06-30
IL205831A0 (en) 2010-11-30
AU2008337570B2 (en) 2012-04-05
CO6290651A2 (es) 2011-06-20
SMP201000095B (it) 2011-09-09
AU2008337570A1 (en) 2009-06-25
EA018014B1 (ru) 2013-04-30
MY150214A (en) 2013-12-13
US8664256B2 (en) 2014-03-04
AR069676A1 (es) 2010-02-10
NZ585142A (en) 2012-03-30
GEP20125647B (en) 2012-09-25

Similar Documents

Publication Publication Date Title
AU2008337570B2 (en) Kinesin inhibitors as cancer therapeutics
CN104363913B (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
US12435030B2 (en) PCNA inhibitors
US10406138B2 (en) Pharmaceutical combinations for treating cancer
Feng et al. Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
KR20220042087A (ko) 엠토르 신호전달 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물
US20190231735A1 (en) Methods for treating cancer
JP2007084494A (ja) Ｐｉｍ−１活性阻害剤
Ding et al. Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285
JP2020506230A (ja) がん、糖尿病および神経障害の処置のための新規スピロおよび環式ビス−ベンジリジンプロテアソーム阻害剤
US12258360B2 (en) Compositions and methods for treatment of anticancer-drug resistant cancers
EP4495115A1 (en) Tetracyclic compound and use thereof
US20080318938A1 (en) Methods for treating aberrant cell proliferation disorders
EP3116954B1 (en) Novel inhibitors for erg oncogene positive cancers
US8772321B2 (en) Heteroannelated anthraquinone derivatives for inhibiting cancers
KR20210107548A (ko) 엠토르 신호전달 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물
WO2020092517A1 (en) Combination therapies for treating cancer
US20190247397A1 (en) Combinatory treatment strategies of cancer based on rna polymerase i inhibition
WO2014152220A1 (en) Identification of candidate target genes for treating neoplasia
US20230227418A1 (en) Usp9x inhibitors
WO2024112258A1 (en) Serotonin receptor as a target for therapy
HK1258659A1 (en) Pcna inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141212